Keyword: Shionogi

Xofluza

44. Xofluza

Xofluza is the first new antiviral flu treatment with a novel mechanism of action approved by the FDA in about two decades.
red blood cells

23. Mulpleta

Mulpleta’s approval was the second thrombopoietin receptor agonist in 2018, trailing Dova Pharmaceutical’s nod for Doptelet by two months.